{"name":"MindRank AI Ltd","slug":"mindrank-ai-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MDR-001","genericName":"MDR-001","slug":"mdr-001","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"MDR-001","genericName":"MDR-001","slug":"mdr-001","phase":"phase_3","mechanism":"MDR-001 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes","Heart failure"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQWkhNc3BFS2prbm9FT1hCbXl5X1d6OVdoaEZxRnE2RWg5RlVySzhXRWdMX201T01WT1lDUXBXc0VuQ0ZjMDBSRHM4a25vVFVya1dDdXROa3BPSUd6aU1CeGEtUzJKUWp2QmRYODFRSEUzS2luaW1tU3E4cTg4dmhORm5zOFlBV3VvZzNtQWxTd0NYTmxFMDhHSU5Ic2ZnOFZGeDhhLUhfNi12OUFpanYxSXFwd0ZUS2w1X0VYMVhqczZvTVJ6ZVNybVVzQzUya0R6TENnYWJzWXV6VmV4OGFBSHJpNkNWaW1fOEZpM2syQmxaZUdRNDNwdDVZZFo2b3BRdXRiRHQ5Q05qSlF2?oc=5","date":"2026-02-25","type":"trial","source":"globenewswire.com","summary":"MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001 - globenewswire.com","headline":"MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxORVk3Q3kxWEJMbzRxOEZqTzdINnlNS25hMUVoQWVtUHFnMUczakhzM21tQjZWYVIxZDhiOGxYTWtLSmJhdU1wWlNtTW00N0JXakswUFktMlVpNWdVZzN5ZWplUm5WY0ZwaXRadEhFNllxNlU3Q2tfSC1lQVlnSTRObEllVHJiWXVt?oc=5","date":"2026-01-05","type":"trial","source":"Yahoo Finance","summary":"MindRank Initiates Phase III \"MOBILE\" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI - Yahoo Finance","headline":"MindRank Initiates Phase III \"MOBILE\" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-04","type":"trial","source":"South China Morning Post","summary":"MindRank in Phase 3 trial with first AI-assisted new drug - South China Morning Post","headline":"MindRank in Phase 3 trial with first AI-assisted new drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxQOVUzVUtiVFNqZHFoOVIycFVlQnNRYjI1dUVhODFpdllOUjBCbjJqZXJGOWVXVUJIZHJNQnUyM21Fc190M3RwZXlfOW54WEhPVkM2LWpVREhfS2EyZ1luTlc5WVZadUFpWGZEbUM5TUhkVzhsaW9KemFCRi1qYXk5aE83c0JWNDRxQ1Y4MUFHTmRSOVRsRTZjNGQ0NGUxTkRiSUlIdzQ3NF9QdEFkeVI1T1IyRDRZZVdZaTZpdks0c21CYTcyN1R1SVY4a25iaUgwNmJpM0ZrbkhnczV2Sk56Z2FXVk0wV3I2X2xwVXk0bm81U1UtUTI0NXVfbFdaajN0WThSdTNqRURhZF9oR1RzZmM1aTl5Szg1RDdXeXdxWnR3ZFVVMngxNDE5dEdUQQ?oc=5","date":"2025-06-24","type":"trial","source":"globenewswire.com","summary":"MindRank Announces Positive Phase 2b Results for - globenewswire.com","headline":"MindRank Announces Positive Phase 2b Results for","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNVzliaHRGT2V5bzdIWFVYNFhBR2RabktuMWV3QXNZRzRtenVnN3dzbzBiVzlJbnJNMDgwU3R4dUlsRlJQS283RVdDWjlYR2hTelk0Qy1nSXVLSzJRU3NpYjRNWGhmZ3c5NldnTUtwUGdYLWR3bnZzY1N1YVNCQW1wNlNtcTRCX1dQb0JTWEVSMndiajRraXZwRFBzZlg5U0JmendERE1BNmhEUjVQREJYbldxMkhwdExyQnZQN1hMd0FDZWFIa1pMN1lIRFNEeXVXcHZZNjFqeUw1bk5aeDN6UkVNamZaLXk1OXBaQjhkWXY2ZnRTcGs5dlNMcXM3Sm5ta3YyV2J4WEowX3dMUGtwUEhFeUZFNDRqaUZ2eTVZcU53QQ?oc=5","date":"2025-03-07","type":"regulatory","source":"globenewswire.com","summary":"Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND - globenewswire.com","headline":"Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9qYzdpbkJESDVJSjRKZWF4d3p4UGxKX21lZ1Bqc2pZWGpkUlR0V3pDWUh3VWdjVkRWZy1MbTFXWmlaREVUQ0l1ZEp0NDlWSDZONmJVLXRCT1dTLTRFS2U4?oc=5","date":"2024-09-10","type":"pipeline","source":"nature.com","summary":"PharmaBench: Enhancing ADMET benchmarks with large language models - nature.com","headline":"PharmaBench: Enhancing ADMET benchmarks with large language models","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE03QmRUcDBHeEtzNnMwOHNyaHpNZWxOQVA0OHA1QXRXV1U4bkZMR0FaWEtSZmVqSW1QekN4MDloY0ZFd2RuSFEtaEd2NWlvSmVfRjVLWUJCRW93S3hkYkVv?oc=5","date":"2023-04-03","type":"pipeline","source":"nature.com","summary":"Pharmacophoric-constrained heterogeneous graph transformer model for molecular property prediction - nature.com","headline":"Pharmacophoric-constrained heterogeneous graph transformer model for molecular property prediction","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}